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Objective: The association between papillary thyroid cancer (PTC) and Hashimoto’s thyroiditis is widely
recognized, but less is known about the possible link between circulating anti-thyroglobulin antibody (TgAb)
titers and PTC aggressiveness. To shed light on this issue, we retrospectively examined a large series of PTC
patients with and without positive TgAb.
Methods: Data on 220 TgAb-positive PTC patients (study cohort) were retrospectively collected in 10
hospital-based referral centers. All the patients had undergone near-total thyroidectomy with or without
radioiodine remnant ablation. Tumor characteristics and long-term outcomes (follow-up range: 2.5–24.8 years)
were compared with those recently reported in 1020 TgAb-negative PTC patients with similar demographic
characteristics. We also assessed the impact on clinical outcome of early titer disappearance in the TgAb-
positive group.
Results: At baseline, the study cohort (mean age 45.9 years, range 12.5–84.1 years; 85% female) had a sig-
nificantly higher prevalence of high-risk patients (6.9% vs. 3.2%, p < 0.05) and extrathyroidal tumor extension
(28.2% vs. 24%; p < 0.0001) than TgAb-negative controls. Study cohort patients were also more likely than
controls to have persistent disease at the 1-year visit (13.6% vs. 7.0%, p = 0.001) or recurrence during sub-
sequent follow-up (5.8% vs. 1.4%, p = 0.0001). At the final follow-up visit, the percentage of patients with
either persistent or recurrent disease in the two cohorts was significantly different (6.4% of TgAb-positive
patients vs. 1.7% in the TgAb-negative group, p < 0.0001). At the 1-year visit, titer normalization was observed
in 85 of the 220 TgAb-positive individuals. These patients had a significantly lower rate of persistent disease
than those who were still TgAb positive (8.2% vs. 17.3%. p = 0.05), and no relapses were observed among
patients with no evidence of disease during subsequent follow-up.
Conclusions: PTC patients with positive serum TgAb titer during the first year after primary treatment were
more likely to have persistent/recurrent disease than those who were consistently TgAb-negative. Negative
titers at 1 year may be associated with more favorable outcomes.
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Introduction
D ifferentiated thyroid cancer (DTC) is the mostcommon of the endocrine cancers. With annual inci-
dence rates ranging from 1 to 10 cases per 100,000, it ac-
counts for 1.7% of all malignancies in the United States
(0.85% of those in men, 2.6% in women) (1). Serum thyro-
globulin (Tg) assays and neck ultrasonography (US) are
currently the mainstays of postoperative surveillance in pa-
tients with DTC (2). The former, however, yields unreliable
results in the presence of circulating anti-thyroglobulin an-
tibodies (TgAbs) (2,3), which are present in about 20% of
patients with DTC (3). In these cases, the current American
Thyroid Association (ATA) guidelines recommend simulta-
neous measurement of TgAb titers and serum Tg levels every
6–12 months (2). Destruction of follicular thyrocytes (normal
and neoplastic) should markedly reduce the levels or even
eliminate these antibodies by removing the antigenic stimu-
lus that drives their production. Stable or increasing serum
TgAb levels during the follow-up of DTC patients are thus
regarded as markers of recurrent/persistent disease. This
correlation has been demonstrated in a number of studies (4–
8), but there are exceptions (9,10).
Moreover, the incidence of positive TgAb and/or anti-
thyroid peroxidase antibody titers in DTC patients is ap-
proximately twofold higher than that of the general population
(3). This finding suggests an association between autoimmune
thyroid disease and papillary thyroid cancer (PTC), although
the nature and prognostic significance of this link has yet to be
defined (3,11–15). Indeed, several groups have examined the
association between PTC aggressiveness and histologically
confirmed thyroiditis or circulating TgAb, but the results that
have emerged have been discordant (5–7,9,15–20).
The aim of this retrospective multicenter study was to
compare two large cohorts of PTC patients with and without
positive serum TgAb titers after primary treatment, to assess
the impact of TgAb positivity on the long-term clinical out-
come. The secondary aim was to evaluate the prognostic
significant of early postoperative titer decreases.
Subjects and Methods
Patients
The protocol for this multicenter retrospective study was
preapproved by the local ethics committee of each partici-
pating center. The requirement for written informed consent
was waived in view of the exclusively observational nature of
the study. The study cohort was selected from the population
of patients consecutively diagnosed with PTC between Jan-
uary 1990 and June 2009 in 10 hospital-based referral centers
for thyroid disease management in Italy. The inclusion cri-
teria were as follows: 1) a positive serum TgAb titer at the
first postoperative assay (1–12 months after primary treat-
ment); 2) complete follow-up data for the 1-year post-
operative visit; and 3) all follow-up data collected at the
participating referral center. The control cohort consisted of
1020 patients with PTC and TgAb titers that were consis-
tently negative for the duration of the postoperative follow-
up. These patients, who were analyzed in a previous study by
our group (21), came from 8 of the 10 referral centers pro-
viding data on the study cohort (TgAb-positive) patients. In
both cohorts, the TgAb status was classified on the basis of
the specific assay and cut-off values used in the center caring
for the patient.
Treatment and postoperative follow-up
The primary treatment consisted of total or near-total
thyroidectomy plus (depending on local policies at the time
of treatment) cervical lymph node dissection (in 51.3% of
the patients) and/or radioiodine remnant ablation (RRA)
(83.6%). The outcome of the primary treatment was assessed
at the 1-year visit in all patients (including those who had also
been evaluated earlier during the first year). Patients were
defined as being without evidence of disease if they did not
show residual tumor tissue detected by neck US or additional
imaging studies. The latter included computed tomography
(CT), magnetic resonance imaging (MRI), or diagnostic 131I
whole-body scans (dxWBS) and were performed as needed
according to clinical evaluation (i.e., aggressive histology
and/or detectable basal serum Tg levels, increasing AbTg
values). Subsequent follow-up visits were scheduled ap-
proximately once a year. Each visit included measurement of
basal and/or stimulated serum Tg levels (immunoradiometric
assays with functional sensitivities ranging from 0.2 to 1 ng/
mL), Tg antibody radioimmunoassays, or immunometric
assays (with cut-offs for negativity that varied from center to
center), and a Doppler ultrasound examination of the neck
performed with multifrequency probes (7.5–12 MHz). The
latter examinations were done by endocrinologists with
specific training and experience in cervical US. Suspicious
neck lesions were confirmed by positive findings on fine-
needle aspiration cytology (FNAC) (i.e., cytological features
of malignancy and/or detectable levels of Tg in the needle
washout fluid). Patients with persistent or recurrent disease
were referred for additional treatment (surgery, radioiodine,
or external-beam radiation, depending on the site of
involvement).
Data collection and analysis
Clinical data collected at each site were retrospectively
transferred to a standard electronic case report form. They
included patient demographics; tumor characteristics (histo-
logical features, baseline tumor stage, and risk for persistent/
recurrent disease as defined by the 2009 ATA Management
Guidelines for Differentiated Thyroid Cancer); treatments
(surgery, RRA, any other intervention); findings (results of
laboratory tests, neck US, and any functional or cross-
sectional imaging study) and disease status at each follow-up
visit; and final outcome (disease status, vital status, cause of
death if applicable).
For the purposes of patient enrollment and the analyses
performed in this study, the results of each TgAb assay were
recorded simply as ‘‘positive’’ or ‘‘negative’’ based on a
titer above or below the cut-off of the specific assay used in
the center where the patient was being followed. Disease
status was defined as ‘‘persistent’’ or ‘‘recurrent’’ only
when measurable lesions were documented by imaging
studies (distant metastases) or by US plus FNAC (thyroid
bed or lymph node disease). The term ‘‘persistent’’ was
used exclusively to refer to disease diagnosed at the 1-year
postoperative visit; disease observed later in the follow-up
was classified as ‘‘recurrence’’ only in patients found to
have no evidence of disease at the 1-year visit. Patients with
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detectable serum Tg values without structural correlates
were considered as being without evidence of disease, un-
less they had significant increases (i.e., ‡50%) in serum
Tg levels with respect to the previous visit(s), or they de-
veloped structural disease during follow-up. In these
cases, they were retrospectively scored as having persistent
disease.
Statistical analysis
Continuous variables are reported as median values and
ranges, while categorical variables are reported as absolute
numbers and percentages. Intergroup differences were as-
sessed with the independent-samples t-test (continuous var-
iables) or the v2 statistic and Fisher exact test (categorical
variables). p-Values <0.05 were considered statistically sig-
nificant. All analyses were performed with StatView 5.0.1
software (SAS Institute Inc., Cary, NC).
Results
Baseline cohort characteristics
Table 1 shows the characteristics of the study cohort
(TgAb positive at the first postoperative visit) and the control
cohort (TgAb negative throughout follow-up) at the time of
primary treatment. The percentage of patients in the study
cohort who were classified as high risk was approximately
twice as high as that of the controls. Although the study
cohort patients had smaller primaries at baseline, they were
also more likely to have gross extrathyroidal disease exten-
sion at baseline. Distant metastasis rates were appreciably but
not significantly higher in the study cohort. These rates reflect
only lesions that were confirmed by 131I WBS following
RRA, which, although not reaching the statistical signifi-
cance, was performed more frequently in control patients
(902 out of 1020; 88.4%) than those of the study cohort (184
out of 220; 83.6%, p = 0.055).
Persistent disease
As shown in Table 2, the percentage of study cohort pa-
tients with persistent disease at the 1-year follow-up visit
was approximately twice as high as that observed among
controls ( p = 0.002). A similar ratio was observed when the
analysis was focused only on patients who had undergone
RRA, being the percentage of persistent disease of 17% in
the study cohort, and 8.4% in controls ( p = 0.002). In 24
(80%) of the 30 patients in the study cohort, the persistent
disease was confined to the thyroid bed or cervical lymph
nodes. The other six also had metastases to the lung, me-
diastinum, and/or bones. While TgAb-positive patients
were more frequently submitted to dxWBS (48% vs. 29%,
p < 0.0001), most of the residual tumor foci that persisted
after primary treatment were detected by cervical US with
comparable rates between the two groups (78% vs. 67%,
respectively).
In both cohorts, the prevalence of persistent disease in-
creased with the ATA risk category ( p < 0.0001 for both),
but in the study cohort, persistence rate among the low-
risk subgroup was significantly higher (7.6% vs. 2.5%,
p < 0.0038). Most of study cohort patients (25/30; 83.3%) and
all 72 controls with persistent disease were retreated (surgery,
RRA, or chemoembolization, depending on the site of in-
volvement) and subsequently re-entered the surveillance
program. At the end of follow-up, 7 out of 30 (23.3%) of
TgAb-positive patients and 14 out of 72 (19.4%) of TgAb-
negative patients still had persistent disease.
Table 1. Characteristics of the Study and Control
Cohorts at the Time of Primary Treatment
Study cohort Controls
Characteristica (n = 220) (n = 1020)
Sex
Male 33 (15) 207 (20.3)
Female 187 (85) 813 (79.7)
Median age
at diagnosis,
years (range)
45.9 (12.5–84.1) 44.0 (13.0–78.0)
Median tumor size,
mm (range)
12 (0.5–50)* 15 (0.3–90)
Tumor focib
Unifocal 140 (63.6) 656 (64.3)
Multifocal 80 (36.4) 364 (35.7)
Unilateral 162 (75.7) 765 (75)
Bilateral 52 (24.3) 255 (25)
Extrathyroidal extension, %
No 158 (71.8) 776 (76)
Microscopic 53 (24.1) 244 (24)
Macroscopic 9 (4.1)** 0 (0)
Lymph node metastasesc
No 157 (71.4) 766 (75)
Yes 63 (28.6) 254 (25)
Distant metastasesd
No 175 (95.1) 869 (96.3)
Yes 9 (4.9) 33 (3.7)
Stage
I 160 (72.7) 753 (73.8)
II 18 (8.2) 82 (8)
III 21 (9.6) 117 (11.4)
IVa 10 (4.5) 41 (4)
IVc 4 (1.8) 15 (1.4)
Unknown 7 (3.2) 12 (1.2)
ATA risk
Low 131 (59.5) 625 (61.3)
Intermediate 74 (33.6) 362 (35.5)
High 15 (6.9)* 33 (3.2)
Radioiodine ablation
Yes 184 (83.6) 902 (88.4)
No 36 (16.4) 118 (11.6)
aUnless otherwise stated, results are reported as numbers (%) of
patients in the study and control cohorts (TgAb-positive and TgAb-
negative, respectively, at the first [1–12 month] posttreatment visit).
bPrimary tumor laterality was unknown for six TgAb-positive
patients.
cThe group without evidence of lymph node metastases includes
both patients who underwent neck dissection with no metastastic
nodes at histology report (pN0) and patients who did not undergo
neck dissection and who had no evidence of lymph node
involvement at neck ultrasonography (cN0).
dData reported only for patients who had post-RRA 131I whole-
body scan to assess distant sites (184/220 study patients, 902/1020
controls). N.B. All patients excluded from the analysis were
classified as low risk, and none had clinically signs suggestive of
extrathyroidal tumor spread.
*p < 0.05.
**p< 0.0001.
ATA, American Thyroid Association; RRA, radioiodine remnant
ablation; TgAb, anti-thyroglobulin antibody.
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Recurrent disease
During the follow-up (median: 5.3 years [range 2.5–24.8]
for the study population, 8.5 years [range 2.7–21.4] for the
controls), recurrences were identified in 11 (5.8%) of the 190
study cohort patients who had been considered without evi-
dence of disease at 1 year. The median time of recurrence was
1.6 years (range 0.7–3.2) after the 1-year visit. Eight of the 11
patients had undergone RRA. Recurrence rates increased
with the baseline ATA risk score (2.3% in the low-risk group,
6.7% in those with intermediate risk, 20% in the high-risk
group, p = 0.008). In nine cases (81.8%), the recurrences were
confined to the thyroid bed or cervical lymph nodes, and in
eight of these, the lesions were diagnosed by US. In the ninth
patient, the US examination was negative, but the previously
stable serum Tg levels had increased. For this reason, a
dxWBS was ordered, and it confirmed the presence of cyto-
logically confirmed tumor tissue regrowth in the thyroid bed
without any lymph-node involvement. The two patients with
distant metastases (pulmonary in both cases) had both been
classified as high risk at baseline, and the lung lesions were
disclosed by CT. In one of the two patients, the CT had been
ordered because locoregional metastases had been detected at
the same visit by US. The second patient had undergone total
thyroidectomy with cervical lymph-node dissection, and the
cervical US examination was negative. In this case, the CT
study had been ordered because of increasing serum TgAb
levels. All 11 patients with recurrent disease were treated
with RRA and/or surgery, and six (55%) were found to have
no evidence of disease at the last follow-up visit.
In the control cohort, the prevalence of recurrences was
significantly lower (1.4%, p= 0.0001), and involvement was
always confined to cervical lymph nodes or the thyroid bed
(21). The percentage of patients with either persistent or re-
current disease at the end of the follow-up was also signifi-
cantly lower than that observed in the TgAb-positive cohort
(1.7% vs. 4.5%, p< 0.017). No significant difference in cancer-
related mortality rates was observed between the study cohort
and the control group (0.4% vs. 0.7%, respectively).
Prognostic role of an early normalization
of TgAb titer and clinical outcome
As shown in Table 3, the total number of patients with
positive titers at the 1-year visit was only 133 (61%). In the
other 85 cases (39%), TgAb titers had become undetectable
since the first postoperative assay at 1 or 3 months. These
patients had a significantly lower rate of persistent disease than
those who were still TgAb positive (8.2% vs. 17.3%. p= 0.05).
Furthermore, analysis of data for the 188 patients who
were without evidence of disease at the 1-year visit revealed
subsequent disease recurrence in 11 (10%) of the 110 who
had remained TgAb-positive but none of the 78 whose titers
were negative at 1 year (Table 3). On the whole, early post-
treatment normalization of TgAb titers (i.e., within the first
year after surgery) was associated with a persistent/recurrent
disease rate three times lower than that observed when titers
were still positive at 1 year (8.2% vs. 25.5%, p = 0.001). Early
normalization thus displayed a negative predictive value for
recurrent disease of 100%, while the positive predictive value
of persistent positivity was 9.0% (specificity 41.1%).
Discussion
Our findings clearly indicate that PTC patients with posi-
tive serum TgAb titers after primary treatment have more
aggressive disease and less favorable long-term outcomes
than demographically similar patients without circulating
TgAbs (21). The differential aggressiveness could already be
observed at the time of primary treatment, when the per-
centage of high-risk patients in the study cohort was twice as
high as that of controls. It was also evident at the 1-year
Table 2. Final Disease Status in Study and Control Cohort Subsets with Diagnoses
of Persistent or Recurrent Disease During Follow-Up
Study cohort Controls
(n= 220) (n= 1020) p-Value
Subsets with persistent diseasea 30 (13.6) 72 (7.1) 0.002
Final disease statusb ns
No imaging-documented disease 20 (66.7) 58 (80.6)
Imaging-documented disease 7 (23.3) 14 (19.4)
Unknownc 3 (10) 0 (0)
Subset with disease recurrenced 11 (5.8) 13 (1.4) 0.0003
Final disease statusb ns
No imaging-documented disease 8 (72.7) 9 (69.2)
Imaging-documented disease 3 (27.3) 3 (23.1)
Unknowne 0 (0) 1 (7.7)
Subset with disease at final follow-upf 10 (4.5) 17 (1.7) 0.017
Results are reported as numbers (%) of patients in the study and control cohorts (TgAb-positive and TgAb-negative, respectively, at the
first [1–12 month] post-treatment visit).
aPersistent disease: disease documented at the 1-year visit; assessed in all 220 study patients and 1020 controls.
bBased on findings at last follow-up visit.
cLost to follow-up immediately after the 1-year visit.
dDisease recurrence: disease documented at any time during follow-up in one of the 190 study patients and 948 controls with no evidence
of persistent disease at 1 year.
eLost to follow-up immediately after recurrent disease was diagnosed.
fDisease at final follow-up: imaging-documented disease at last follow-up visit.
ns, not significant.
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follow-up visit, when persistent and recurrent disease rates
were approximately two and three times higher, respectively,
than those of controls, and at the final follow-up visit, when
the disease rate was roughly three times higher than that of
the patients who had never presented Tg-Ab positivity. Pa-
tients with positive TgAb were more frequently submitted to
dxWBS, but the number of US examinations was comparable
in the two groups. However, given that most of the persistent
and recurrent disease was confined to the neck and was de-
tected by US (78% in TgAb-positive patients and 67% in
TgAb-negative patients) rather than dxWBS, the difference
in imaging procedures should have not influenced the results.
In other words, the higher prevalence of persistent/recurrent
disease in TgAb-positive patients is unlikely to depend on the
higher number of dxWBS performed.
Our results also tend to confirm the favorable prognostic
significance of early normalization of serum TgAb titers re-
ported by several groups (4,5,7). Indeed, at the first control
visit the prevalence of persistent disease was half in patients
with normalization of TgAb compared to those with titers that
were still positive. Moreover, none of the patients with no
evidence of disease and early TgAb normalization relapsed as
compared to 10% of those with titers that were still positive.
The association between PTC and lymphocytic thyroiditis
is widely recognized (3,13,14,22,23), but the impact of Ha-
shimoto’s thyroiditis (HT) and circulating TgAb on PTC
patients remains a controversial issue (12,15–17,20,23). HT
is more frequent in young women, whose age alone is a fa-
vorable prognostic factor (in terms of no evidence of disease
intervals and mortality) (3,15,17–19). In a recent meta-
analysis of 38 studies, PTCs with histologically proven HT
(23.8%) were negatively associated with extrathyroidal ex-
tension ( p = 0.002) and lymph node metastasis at baseline
( p = 0.04) (15). Findings of this type have led some investi-
gators to speculate that the autoimmune response to thyroid-
specific antigens in patients with HT enhances the destruction
of cancer cells expressing thyroid-specific antigen in PTC,
thereby reducing the risk of recurrence and improving sur-
vival (3,18,19). In other studies, however, the prognosis for
PTC patients with HT was similar to or worse than that of
PTC patients without HT (6,12,24–27). A recent study on
papillary thyroid microcarcinomas, for example, revealed
higher frequencies of bilateral and/or multifocal involvement
as well as of lymph node metastases in patients with con-
comitant lymphocytic thyroiditis (26).
A very recent review of the surgical pathology archives of
the Johns Hopkins Hospital showed that recent increases in
the incidence of PTC include cases associated with full-
blown HT and others associated with a milder form of lym-
phocytic infiltration known as chronic nonspecific thyroiditis.
These findings suggest that PTC and lymphocytic infiltration
may not be part of the same causal pathway: instead, neo-
plastic transformation of the thyrocyte may trigger the lym-
phocytic response, which may or may not progress to HT
(13). Therefore, the clinical implications of cross-talk be-
tween the tumor and its inflammatory microenvironment are
still poorly understood. In this setting, it is widely recognized
that TgAbs are less diagnostic for HT than anti-thyroid per-
oxidase antibodies and more tumor specific as supported by
epitope mapping studies (28). Thus, one should distinguish
between a positive TgAb titer associated with underlying HT
or one arising as a response to tumorigenesis and associated
inflammation. Overall, these findings may explain the con-
troversial results in the scientific literature regarding the
impact of thyroid autoimmunity on PTC development and
aggressiveness. Given these considerations, the lack of in-
formation concerning histological lymphocytic infiltration of
thyroid tissue represents a limitation of the current study,
although it is multicentric and carried out in a large number of
patients. Future studies with closer investigation of the his-
tological features of lymphocytic infiltrates in TgAb-positive
patients are warranted.
Several studies have highlighted the link between long-
standing TgAb positivity and persistent/recurrent disease in
PTC patients (4,5,7,8). Eradication of follicular cells, by
eliminating the antigenic stimulus, should in fact lead to a
progressive decline in TgAb levels and ultimately their com-
plete disappearance. Persistently positive titers are viewed as
evidence of the continued presence of functional thyroid cells,
benign or malignant (3,29). Our findings support the view that
early disappearance of TgAb titers is a prognostically favor-
able finding in patients with PTC.
In conclusion, our data indicate that PTC patients with
positive postoperative serum TgAb titers are more likely to
have persistent/recurrent disease than similar patients who
are consistently TgAb negative. Disappearance of TgAb
Table 3. Disease and TgAb Status in the Study Cohort at the 1-Year and Final Follow-Up Visits
TgAb status
Positive Negative p-Value
1-year follow-up visita n = 133 (61.0%) n = 85 (39.0%)
Persistent diseaseb 23 (17.3) 7 (8.2) 0.05
Recurrent diseasec 11 (10) 0 (0) 0.003
Persistent/recurrent disease 34 (25.5) 7 (8.2) 0.001
Final follow-up visitd n = 47 (21.7) n= 168 (77.4)
No imaging-documented disease 40 (85.1) 161 (95.8) 0.015
Imaging-documented disease 7 (14.9) 7 (4.2)
Results are reported as numbers (%) of patients with positive and negative TgAb.
aAnalysis limited to 218/220 patients with known TgAb status at this time point.
bPersistent disease: disease documented at the 1-year visit; assessed in 133 TgAb-positive patients and 85 TgAb-negative patients.
cRecurrent disease: disease documented at any time during follow-up in one of the 110 TgAb-positive and 78 TgAb-negative patients
with no evidence of persistent disease at 1-year.
dAnalysis limited to 215/220 patients with known TgAb status at this time point.
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titers within the first postoperative year seems to be associ-
ated with a more favorable prognosis.
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